Abstract
The Brighton Collaboration (BC) has formulated a number of case definitions which have primarily been applied to adverse events of special interest in the context of vaccine safety surveillance. This is a revision of the 2007 BC case definition for anaphylaxis. Recently, the BC definition has been widely used for evaluating reports of suspected anaphylaxis following COVID-19 vaccination. This has led to debate about the performance of the BC definition in comparison with those from the US National Institute of Allergy and Infectious Disease/Food Allergy Anaphylaxis Network (NIAID/FAAN) and the World Allergy Organization (WAO). BC convened an expert working group to revise the case definition based on their usual process of literature review and expert consensus. This manuscript presents the outcome of this process and proposes a revised case definition for anaphylaxis. Major and minor criteria have been re-evaluated with an emphasis on the reporting of observable clinical signs, rather than subjective symptoms, and a clearer approach to the ascertainment of levels of certainty is provided. The BC case definition has also been aligned with other contemporary and international case definitions for anaphylaxis.
| Original language | English |
|---|---|
| Journal | Vaccine |
| DOIs | |
| Publication status | Accepted/In press - 2022 |
Bibliographical note
Funding Information:This work was supported by the Coalition for Epidemic Preparedness Innovations (CEPI) under a service order entitled Safety Platform for Emergency vACcines (SPEAC) Project with the Brighton Collaboration, a program of the Task Force for Global Health, Decatur, GA.
Funding Information:
The authors are grateful for the support and very helpful comments provided by the Brighton Collaboration Steering Committee, as well as other experts consulted as part of the process. The authors are also grateful to Margaret Haugh for writing and editorial support. Matthew Greenhawt reports personal fees from Aquestive, DBV Technologies, Sanofi/Regeneron, Nutricia, Novartis, Acquestive, Allergy Therapeutics, AstraZeneca, ALK-Abello, Prota, ImSci, MedLearningGroup, RMEI Medical Education; stipend for service as the senior associate editor for the Annals of Allergy, Asthma, and Immunology; and is member of the Joint Taskforce on Allergy Practice Parameters guidelines committee. Paul J Turner reports grants from UK Medical Research Council, NIHR/Imperial BRC and JM Charitable Foundation; personal fees from UK Food Standards Agency, Aimmune Therapeutics, Allergenis, Aquestive Therapeutics and Novartis. This work was supported by the Coalition for Epidemic Preparedness Innovations (CEPI) under a service order entitled Safety Platform for Emergency vACcines (SPEAC) Project with the Brighton Collaboration, a program of the Task Force for Global Health, Decatur, GA.
Funding Information:
Matthew Greenhawt reports personal fees from Aquestive, DBV Technologies, Sanofi/Regeneron, Nutricia, Novartis, Acquestive, Allergy Therapeutics, AstraZeneca, ALK-Abello, Prota, ImSci, MedLearningGroup, RMEI Medical Education; stipend for service as the senior associate editor for the Annals of Allergy, Asthma, and Immunology; and is member of the Joint Taskforce on Allergy Practice Parameters guidelines committee. Paul J Turner reports grants from UK Medical Research Council, NIHR/Imperial BRC and JM Charitable Foundation; personal fees from UK Food Standards Agency, Aimmune Therapeutics, Allergenis, Aquestive Therapeutics and Novartis.
Publisher Copyright:
© 2022 Elsevier Ltd
ASJC Scopus Subject Areas
- Molecular Medicine
- General Immunology and Microbiology
- General Veterinary
- Public Health, Environmental and Occupational Health
- Infectious Diseases
PubMed: MeSH publication types
- Journal Article
